Trial Profile
Pharmacokinetics, safety and immunogenicity of single doses of belatacept administered subcutaneously to healthy subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Belatacept (Primary) ; Belatacept (Primary)
- Indications Transplant rejection
- Focus Pharmacokinetics
- 29 Sep 2008 Planned number of patients changed from 154 to actual number 47 as reported by ClinicalTrials.gov.
- 10 Sep 2008 Actual start date changed from Jun 2008 to Aug 2008 as reported by Clinicaltrials.gov.
- 10 Sep 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.